levodopa has been researched along with 6-methyl-2-(phenylethynyl)pyridine in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bergmann, R; Gasparini, F; Kuhn, R; Spooren, WP | 1 |
| Amalric, M; Baunez, C; Breysse, N; Turle-Lorenzo, N | 1 |
| Coccurello, R; Domenici, MR; Martire, A; Pèzzola, A; Popoli, P; Potenza, RL; Reggio, R; Tebano, MT | 1 |
| Armentero, MT; Bazzini, E; Blandini, F; Levandis, G; Nappi, G | 1 |
| Amalric, M; De Leonibus, E; Giordani, F; Lopez, S; Managò, F; Mele, A; Oliverio, A; Petrosino, F | 1 |
| Aguilar, E; Bonastre, M; Jiménez, A; Marin, C | 2 |
| Soghomonian, JJ; Yamamoto, N | 1 |
| Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N | 1 |
| Desrayaud, S; Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N; Morissette, M | 1 |
| Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N; Morissette, M | 1 |
| Di Paolo, T; Grégoire, L; Jourdain, VA; Morin, N; Morissette, M | 1 |
| Di Paolo, T; Grégoire, L; Morin, N; Morissette, M | 1 |
| Bilbe, G; Bouhelal, R; Desrayaud, S; Enz, A; Flor, PJ; Gasparini, F; Kuhn, R; McAllister, K; Ofner, S; Vranesic, I | 1 |
| Ambrosi, G; Antoninetti, G; Baqi, Y; Blandini, F; Cerri, S; Costa, G; Fuzzati-Armentero, MT; Levandis, G; Montepeloso, E; Müller, CE; Pinna, A; Simola, N; Volpini, R | 1 |
| Di Paolo, T; Grégoire, L; Morin, N; Morissette, M; Rajput, A; Rajput, AH | 2 |
17 other study(ies) available for levodopa and 6-methyl-2-(phenylethynyl)pyridine
| Article | Year |
|---|---|
Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats.
Topics: Animals; Apomorphine; Dextroamphetamine; Dizocilpine Maleate; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Oxidopamine; Pyridines; Rats; Rats, Wistar; Receptors, Metabotropic Glutamate; Rotation | 2000 |
Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dizocilpine Maleate; Drug Synergism; Levodopa; Male; Parkinsonian Disorders; Pyridines; Rats; Rats, Wistar; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate | 2005 |
Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6-hydroxydopamine-lesioned rats: possible relevance to the effects of mGlu5R blockade in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Denervation; Drug Interactions; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glycine; Levodopa; Male; Organ Culture Techniques; Oxidopamine; Parkinson Disease; Phenylacetates; Pyridines; Rats; Rats, Wistar; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Sympatholytics; Tritium | 2005 |
Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Subthalamic Nucleus; Time Factors; Tyrosine 3-Monooxygenase | 2008 |
Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease.
Topics: Animals; Association Learning; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Levodopa; Male; Memory Disorders; Mice; Movement; Oxidopamine; Parkinson Disease; Pyridines; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Space Perception; Vision Disorders | 2009 |
Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Carrier Proteins; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Homer Scaffolding Proteins; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2009 |
Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Dopamine Agents; Dynorphins; Dyskinesia, Drug-Induced; Dystonia; Excitatory Amino Acid Antagonists; Glutamate Decarboxylase; Levodopa; Male; Neurons; Oxidopamine; Protein Precursors; Pyridines; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; RNA, Messenger | 2009 |
Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Levodopa; Locomotion; Macaca fascicularis; Parkinsonian Disorders; Pyridines; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Severity of Illness Index; Thiazoles; Time Factors; Treatment Outcome | 2010 |
The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L-DOPA-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Down-Regulation; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Parkinsonian Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Vesicular Glutamate Transport Protein 2 | 2011 |
MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Administration Schedule; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Levodopa; Macaca fascicularis; Oximes; Parkinsonian Disorders; Putamen; Pyridines; Radioligand Assay; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate | 2013 |
Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Topics: 2-Amino-5-phosphonovalerate; Amino Acids; Animals; Basal Ganglia; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Imidazoles; Levodopa; Macaca fascicularis; Oximes; Parkinsonian Disorders; Phenols; Piperidines; Pyridines; Quinazolines; Radioligand Assay; Receptor, Metabotropic Glutamate 5; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Tritium; Xanthenes | 2013 |
Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Levodopa; Macaca fascicularis; MAP Kinase Signaling System; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-akt; Pyridines; Receptor, Metabotropic Glutamate 5; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger | 2014 |
Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Brain; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Homovanillic Acid; Levodopa; Macaca fascicularis; Ovariectomy; Parkinsonian Disorders; Protein Binding; Pyridines; Serotonin | 2015 |
AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization.
Topics: Animals; Brain; Dyskinesia, Drug-Induced; Half-Life; High-Throughput Screening Assays; Humans; Hyperthermia, Induced; Indoles; Levodopa; Male; Mice; Protein Binding; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Structure-Activity Relationship | 2014 |
Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson's disease.
Topics: Adenine; Animals; Drug Delivery Systems; Drug Synergism; Levodopa; Male; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Pyridines; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Rotation; Treatment Outcome; Xanthines | 2015 |
Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications.
Topics: Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Brain; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Ovariectomy; Parkinson Disease; Pyridines; Receptor, Metabotropic Glutamate 5; Receptor, Serotonin, 5-HT1B | 2015 |
Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antiparkinson Agents; Bungarotoxins; Case-Control Studies; Caudate Nucleus; Corpus Striatum; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Gene Expression; Humans; Iodine Radioisotopes; Levodopa; Macaca fascicularis; Male; Organ Specificity; Ovariectomy; Parkinson Disease; Parkinson Disease, Secondary; Putamen; Pyridines; Signal Transduction | 2016 |